Ahmed Gawish

The #NeuroRNA team really enjoyed attending the #CancerNeuroscience meeting organised by the #EACR this week in #Bilbao. Josune Alonso and Ane Rubio presented their projects in #RNA misprocessing in #GBM @biogipuzkoa.bsky.social @helloeacr.bsky.social

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial PURPOSEThe EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among pa...

Congrats to Ethan Ludmir and Chad Tang for their publication selected for recognition as part of @mdanderson.bsky.social Excellence in Science Award. #radonc #endcancer

ascopubs.org/doi/10.1200/...

Interested in #reirradiation heading to the first full day of #ESTRO25? Why not follow our
🔹Reirradiation Journey🔹
through the conference programme! Find it in the programme filter options - or below #radonc #medphys

✨We're thrilled to be taking part in #ESTRO25 in Vienna!

EORTC researchers will be presenting cutting-edge findings in #RadiationOncology, a cornerstone of our scientific strategy.

Find out more: www.eortc.org/blog/2025/05...

@estroradiotherapy.bsky.social #CancerResearch

What a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy

The phase III NRG/RTOG 0920 trial explored adding cetuximab to postoperative radiotherapy (RT) in 577 patients with resected intermediate-risk SCCHN.

📊 Key Findings @ascocancer.bsky.social #JCO

#Onco404 #Cancer #Kanser #Oncology #HeadAndNeckCancer #RadiationTherapy #Cetuximab #ClinicalTrials #HPV

In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing:
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch

durvalumab plus tremelimumab with concurrent radiotherapy : 81% CR
#radonc #GU

Treatment of Pleural Mesothelioma: ASCO Guideline Update

https://buff.ly/3WrRMUm

The ASCO guidelines for pleural #mesothelioma (PM) provide evidence-based recommendations for physicians on managing this condition. #LungCancer

bevacizumab, a VEGF inhibitor, in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.

https://buff.ly/40qpx9W

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating...

Nivolumab Improves DFS in High-Risk Head & Neck SCC

The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis.

Our latest study, "Pulmonary Stereotactic Body Radiotherapy (SBRT) of Oligometastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC): A Multicenter Retrospective Study", is now available in the @ijrobp.bsky.social

www.redjournal.org/article/S036...

In Greenland, as we speak.

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.

Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...

The RACE-GB trial results are here! FIRST randomized controlled trial investigating radiotherapy (RT) in gallbladder cancer.

In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc

#RadOnc starter pack loading! Please let me know if you would like to be added.

go.bsky.app/TbynCkm

#oncsky #bcsm #gyncsm #hncsm

Radiation Oncology is characterized by rapid innovation

Dissemination & implementation are important aspects to bring this progress to our cancer patients in daily practice

Well written review by Erin Gillespie and colleagues 👇
www.redjournal.org/article/S036...

Great list , please add me

Great , please add me to the list

Please add me #radonc

Hi , I’d like to be included